eyeforpharma Philadelphia 2018

Apr 10, 2018 - Apr 11, 2018, Philadelphia

Be the trusted healthcare partner

An Ode To Efficiency

A multi-pronged approach to improving a common hospital procedure wins distinguished award

Human error is always a tough pill to swallow, especially in healthcare, where man-made decisions have a tangible impact on resource allocation, procedures and ultimately patient outcomes. But the upside is that we can also learn from our mistakes.

Medical technology company BD has been awarded for its dynamic resolve in righting the wrongs of healthcare inefficiency, scooping the Most Valuable HCP Initiative award for its BD Vascular Access Management (VAM) program.      

In crowning the initiative, the panel of expert judges – comprising patients, patient advocates, healthcare professionals and senior pharma executives – praised it for setting the benchmark for other companies trying to reform areas of healthcare.

Intravenous catheterization is the most common invasive procedure, performed on up to 90% of hospital inpatients. However, up to half of IVs fail, largely due to preventable complications, a poor outcome for the clinician, hospital, and most importantly, patient.

The impact of these failures is widespread. For the patient, complications and the restarts they require are both painful and risky and can delay treatment and extend length of stay. They may begin to question the skills of the clinician, who is also impacted, at times experiencing anxiety or stress. For hospitals, reputations can suffer as patient satisfaction is impacted, the costs of increased product usage and lost efficiency can really add up; billions of dollars are wasted in today’s inefficient and under-effective environment.  

BD Vascular Access Management (VAM) is an integrated program to help hospitals dramatically reduce those complications. This uniquely integrated approach, partners with customers to perform rigorous clinical practice assessments, make recommendations to align to best practices and guidelines, and then help implement those recommendations with best-in-class products and robust training and education programs.

The concerted push has paid dividends. VAM customers reported a 32% reduction in complications and a 37% improvement in first-stick success. For one customer, this led to a 15-point improvement in their patient satisfaction scores and a 12% cost savings.

The other finalists for the Most Valuable HCP Initiative were:

Augmented and Virtual Reality Experience — Pixacore, Bayer Oncology

 Using virtual reality headsets, the HCPs were free to roam through a virtual world that portrayed seven investigational pathways being pursued by Bayer Oncology. Each pathway included an animated narrative about research into the innovative mechanism, and new approaches to treating cancer.

Interactive ALSFRS-R Digital Detail — Mitsubishi Tanabe Pharma America, inVentiv Health

The Interactive ALSFRS-R digital detail was developed to help neurologists understand the ALS Functional Rating Scale-Revised (ALSFRS-R), a clinical tool used to evaluate loss of physical function in people with ALS, using an innovative, user-friendly presentation to transform a text-heavy evaluation tool into a memorable, intuitive, emotionally impactful experience.

Patient Assessment in COPD (PAC)Boehringer Ingelheim and CTC Communications

Chronic Obstructive Pulmonary Disease (COPD) is a leading chronic debilitating condition, yet appropriate assessment of patients continues to pose multiple challenges and lead to inappropriate management of the condition. Boehringer Ingelheim and CTC communications developed a digital point-of-care tool, Vivomap, to receive both feedback from patients and clinical inputs from HCPs to share recommendations based on international GOLD guidelines for the management of COPD.





Since you're here...
... and value our content, you should sign-up to our newsletter. Sign up here

eyeforpharma Philadelphia 2018

Apr 10, 2018 - Apr 11, 2018, Philadelphia

Be the trusted healthcare partner